Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
Nicole Baca
Summary
This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to estimate the positive predictive value of changes in Magnetic Resonance Imaging scans from baseline to 12-month visit using an Artificial Intelligence algorithm, among 15 pediatric patients with neurofibromatosis type 1 at Cedars-Sinai Medical Center.
Eligibility
- Age range
- 5–17 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Between the ages of 5 and \<18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll. * Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental NF-1 also qualify for the study. Exclusion Criteria: * Requiring sedation for imaging. * Implants and/or Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies * Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards. * Allergy to animal dander or animal-instigated asthm…
Interventions
- OtherWhole-body Magnetic Resonance Imaging
Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
Location
- Cedars Sinai Medical CenterLos Angeles, California